Evidence map›Paper›PMID 32313651›Full record

ReviewClinical & translational immunology2020

Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.

Sarah A Robertson, Mark R Hutchinson, Kenner C Rice, Peck-Yin Chin, Lachlan M Moldenhauer, Michael J Stark, David M Olson, Jeffrey A Keelan

Open access · goldAbstract readReview
In one paragraph

Review in Clinical & translational immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Impact of Sociodemographic, Clinical, and Genetic Factors andIranian journal of medical sciences · 2025
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. The relationship between Toll-like receptor-4 genes and preeclampsia outcomes.Journal of assisted reproduction and genetics · 2024
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Sarah A RobertsonRobinson Research Institute and Adelaide Medical School University of Adelaide Adelaide SA Australia.ORCID https://orcid.org/0000-0002-9967-0084
Mark R HutchinsonRobinson Research Institute and Adelaide Medical School University of Adelaide Adelaide SA Australia.ORCID https://orcid.org/0000-0003-2154-5950
Kenner C RiceDrug Design and Synthesis Section National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism National Institutes of Health Rockville MD USA.
Peck-Yin ChinRobinson Research Institute and Adelaide Medical School University of Adelaide Adelaide SA Australia.ORCID https://orcid.org/0000-0002-0923-0553
Lachlan M MoldenhauerRobinson Research Institute and Adelaide Medical School University of Adelaide Adelaide SA Australia.ORCID https://orcid.org/0000-0002-3141-2521
Michael J StarkRobinson Research Institute and Adelaide Medical School University of Adelaide Adelaide SA Australia.
David M OlsonDepartment of Obstetrics and Gynecology Department of Physiology and Pediatrics 220 HMRC University of Alberta Edmonton AB Canada.ORCID https://orcid.org/0000-0003-0080-997X
Jeffrey A KeelanDivision of Obstetrics & Gynaecology University of Western Australia Perth WA Australia.ORCID https://orcid.org/0000-0002-5403-6266
The University of Adelaide · AUNational Institute on Drug Abuse · USThe University of Western Australia · AUUniversity of Alberta · CA

Funding

Medicinal Chemistry of Drugs Acting on Toll-like ReceptorsZIADA000530 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.0M
6 · The paper itself

Abstract

Every year, 15 million pregnancies end prematurely, resulting in more than 1 million infant deaths and long-term health consequences for many children. The physiological processes of labour and birth involve essential roles for immune cells and pro-inflammatory cytokines in gestational tissues. There is compelling evidence that the mechanisms underlying spontaneous preterm birth are initiated when a premature and excessive inflammatory response is triggered by infection or other causes. Exposure to pro-inflammatory mediators is emerging as a major factor in the 'fetal inflammatory response syndrome' that often accompanies preterm birth, where unscheduled effects in fetal tissues interfere with normal development and predispose to neonatal morbidity. Toll-like receptors (TLRs) are critical upstream gatekeepers of inflammatory activation. TLR4 is prominently involved through its ability to sense and integrate signals from a range of microbial and endogenous triggers to provoke and perpetuate inflammation. Preclinical studies have identified TLR4 as an attractive pharmacological target to promote uterine quiescence and protect the fetus from inflammatory injury. Novel small-molecule inhibitors of TLR4 signalling, specifically the non-opioid receptor antagonists (+)-naloxone and (+)-naltrexone, are proving highly effective in animal models for preventing preterm birth induced by bacterial mimetic LPS, heat-killed

Indexed as

fetal inflammatory injuryinflammationpregnancypretermTLR4 antagonistToll‐like receptor 4

Identifiers

PMID32313651
PMCPMC7156293
OpenAlexW3016869816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.